An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of IXAZOMIB (MLN9708) Administered Weekly in Adult Patients With Relapsed or Refractory Light-Chain Amyloidosis Who Require Further Treatment
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2018
Price : $35 *
At a glance
- Drugs Ixazomib (Primary)
- Indications Amyloidosis
- Focus Adverse reactions
- Sponsors Takeda Oncology
- 19 Nov 2018 Status changed from active, no longer recruiting to completed.
- 24 Oct 2018 Planned End Date changed from 18 Sep 2018 to 13 Nov 2018.
- 24 Aug 2018 Planned End Date changed from 31 Aug 2018 to 18 Sep 2018.